Compare 22nd Century Group (XXII) With Other Cannabis Stocks
Head-to-head stock comparisons across price, valuation, financials, and growth metrics
22nd Century Group (XXII)
$0.0420
-13.04%
$30.0K
Biotech
Biotech Sector Peers
All Biotech cannabis companies sorted by market capitalization. Click any ticker to see a detailed head-to-head comparison.
Top Matchups by Market Cap
Companies closest to 22nd Century Group in market capitalization — the most meaningful head-to-head comparisons.
Cross-Sector Comparisons
Top cannabis companies outside the Biotech sector. Compare across different business models and market segments.
Scotts Miracle-Gro
MCap: $3.91B
Curaleaf Holdings
MCap: $2.61B
Trulieve Cannabis
MCap: $2.23B
Innovative Industrial Properties
MCap: $1.55B
Green Thumb Industries
MCap: $1.53B
Comparing XXII in the Cannabis Market
22nd Century Group (XXII) is a cannabis biotech companytrading at $0.0420 per share with a market capitalization of $30.0K. Among its Biotech peers, XXII ranks #4 by market cap, with trailing twelve-month revenue of $14.5M. The stock has moved -13.04% in the current session, trading on the NASDAQ exchange.
When comparing XXII against other cannabis stocks, investors should consider key financial metrics including price-to-sales ratio (0.0x), revenue growth (-27.44% YoY), and balance sheet strength (cash of $6.1M vs. debt of $560.0K). The comparison tables above allow you to evaluate 22nd Century Group relative to 3 sector peers and leading companies across all cannabis sub-sectors, helping you identify which stocks offer better value, stronger growth, or more favorable risk profiles.
Frequently Asked Questions
How does XXII compare to other Biotech stocks?+
What is XXII's biggest competitor?+
Is XXII overvalued compared to its peers?+
Which cannabis stock has better margins than XXII?+
Can I compare XXII to stocks in other cannabis sectors?+
All XXII Comparisons
Every available head-to-head comparison for 22nd Century Group.
Related Pages
Disclaimer: The comparison data on this page is for informational purposes only and does not constitute financial advice, investment recommendations, or an endorsement of any security. Cannabis stocks are highly volatile and subject to unique regulatory risks. Always conduct your own research and consult a licensed financial advisor before making investment decisions.Cannabismarketcap does not guarantee the accuracy or completeness of any data presented.